<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848211</url>
  </required_header>
  <id_info>
    <org_study_id>THYMON-08001</org_study_id>
    <nct_id>NCT00848211</nct_id>
  </id_info>
  <brief_title>Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects</brief_title>
  <acronym>THYMON-08001</acronym>
  <official_title>Phase I/IIA Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thymon, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thymon, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol represents the first in human study of TUTI-16, and is being conducted to
      establish the safety and human immunogenicity (anti-HIV-1 Tat titers) of subcutaneously
      administered TUTI-16. Activity of TUTI-16 will also be determined in minimizing HIV-1 viral
      loads and sustaining CD4+ T-cell levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 Tat protein, a virally encoded toxin, is secreted by HIV-1 infected cells and acts on
      uninfected cells, rendering them permissive for HIV-1 replication. HIV-1 Tat enhances chronic
      viral replication and induces immune suppression. Antibodies to Tat inhibit this Tat-mediated
      transcellular activation in vitro and minimize chronic plasma viremia. HIV-1 Tat activities
      can be blocked in vitro and in vivo by anti-Tat antibodies.

      The Thymon Universal Tat Immunogen (TUTI-16) is a fully synthetic, self-adjuvanting
      lipopeptide vaccine that is water soluble and administered by subcutaneous injection. In
      preclinical studies, a priming dose and a three week boost in rats induced a high titer
      antibody response to the eight known distinct epitope variants of HIV-1 Tat protein. These
      antibodies block the function of the HIV-1 Tat protein (toxin), which is essential to the
      maintenance of chronic HIV-1 viremia. Therefore, TUTI-16 has potential as a therapeutic
      vaccine for HIV-1 in humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Viral Load</measure>
    <time_frame>baseline and 20 weeks</time_frame>
    <description>Change in HIV viral load from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ T-cell Count</measure>
    <time_frame>baseline and 20 weeks</time_frame>
    <description>Change in CD4+ T-cell count from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of Anti-Tat Antibodies</measure>
    <time_frame>baseline and 16 weeks</time_frame>
    <description>Determination of change in anti-Tat antibody level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TUTI-16 0.03 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection on Day 0, Day 28, and Day 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TUTI-16 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection on Day 0, Day 28, and Day 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TUTI-16 0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection on Day 0, Day 28, and Day 84</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection on Day 0, Day 28, and Day 84</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TUTI-16 (0.03mg)</intervention_name>
    <description>Subcutaneous injection on Day 0, Day 28, and Day 84</description>
    <arm_group_label>TUTI-16 0.03 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TUTI-16 (0.1mg)</intervention_name>
    <description>Subcutaneous injection on Day 0, Day 28, and Day 84</description>
    <arm_group_label>TUTI-16 0.1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TUTI-16 (0.6mg)</intervention_name>
    <description>Subcutaneous injection on Day 0, Day 28, and Day 84</description>
    <arm_group_label>TUTI-16 0.6 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  Age ≥18 and ≤50 years at Screening

          -  HIV-1 seropositive

          -  asymptomatic and in generally good health

          -  no prior anti-retroviral therapy within 6 months of screening

          -  viral load ≥ 3,000 ≤ 100,000 HIV-1 RNA copies/mL

          -  CD4+ T-cell count ≥ 400/mm3.

        Exclusion Criteria:

          -  Pregnant/nursing females

          -  positive for HBV or HCV

          -  acute Herpetic event

          -  any clinically significant out-of range laboratory value

          -  subject is unable or unwilling to discontinue during the study

          -  participation in another investigational drug/vaccine study within 30 days preceding
             the first injection of investigational agent in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus A Conant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Conant Medical Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Conant Medical Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <results_first_submitted>June 12, 2010</results_first_submitted>
  <results_first_submitted_qc>January 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2011</results_first_posted>
  <last_update_submitted>February 17, 2011</last_update_submitted>
  <last_update_submitted_qc>February 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gideon Goldstein, MD, PhD</name_title>
    <organization>THYMON, LLC</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>vaccine</keyword>
  <keyword>lipopeptide</keyword>
  <keyword>Tat</keyword>
  <keyword>TUTI-16</keyword>
  <keyword>THYMON</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (0.03mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (0.1mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (0.6mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (0.03mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (0.1mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (0.6mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="10"/>
                    <measurement group_id="B2" value="48" spread="9"/>
                    <measurement group_id="B3" value="41" spread="8"/>
                    <measurement group_id="B4" value="51" spread="5"/>
                    <measurement group_id="B5" value="45.9" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HIV Viral Load</title>
        <description>Change in HIV viral load from baseline</description>
        <time_frame>baseline and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (0.03mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (0.1mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (0.6mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load</title>
          <description>Change in HIV viral load from baseline</description>
          <units>HIV RNA copies/mL</units>
          <param>Log Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.12"/>
                    <measurement group_id="O2" value="-0.05" spread="0.13"/>
                    <measurement group_id="O3" value="0.002" spread="0.11"/>
                    <measurement group_id="O4" value="0.26" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Anti-Tat Antibodies</title>
        <description>Determination of change in anti-Tat antibody level</description>
        <time_frame>baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (0.03mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (0.1mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (0.6mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Anti-Tat Antibodies</title>
          <description>Determination of change in anti-Tat antibody level</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="20" upper_limit="456"/>
                    <measurement group_id="O2" value="84" lower_limit="20" upper_limit="181"/>
                    <measurement group_id="O3" value="84" lower_limit="20" upper_limit="642"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4+ T-cell Count</title>
        <description>Change in CD4+ T-cell count from baseline</description>
        <time_frame>baseline and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (0.03mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (0.1mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (0.6mg TUTI-16)</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Count</title>
          <description>Change in CD4+ T-cell count from baseline</description>
          <units>cells/mm3</units>
          <param>Log Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65" spread="48"/>
                    <measurement group_id="O2" value="-116" spread="56"/>
                    <measurement group_id="O3" value="14" spread="53"/>
                    <measurement group_id="O4" value="-59" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (0.03mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (0.1mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (0.6mg TUTI-16)</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Subcutaneous injection over the deltoid muscle in the upper arm on Day 0, Day 28, and Day 84</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <description>nausea, vomitting, diarrhea, abdominal pain upper</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <description>Injection site tenderness, irritation, erythema, pain, induration, swelling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscular weakness</sub_title>
                <description>fatigue, myalgia, muscular weakness, arthralgia,</description>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gideon Goldstein, MD, PhD</name_or_title>
      <organization>Thymon LLC</organization>
      <phone>(973) 467-9558</phone>
      <email>gidgold@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

